Alphamab’s KN026 Phase III Breast Cancer Trial Hits Key Efficacy Goal

Alphamab Oncology ( (HK:9966) ) has provided an announcement.

Alphamab Oncology said its phase III Neo-Healer trial of KN026, an anti-HER2 bispecific antibody, combined with CSPC Group’s HB1801 as neoadjuvant therapy for early or locally advanced HER2-positive breast cancer met its primary endpoint, showing a highly significant improvement in total pathological complete response versus the current standard of care. The result strengthens KN026’s profile alongside its ongoing registrational studies and existing U.S. orphan drug and China breakthrough designations in gastric cancer, while deepening Alphamab’s collaboration with CSPC and potentially enhancing its competitive positioning in HER2-targeted oncology across breast and gastric cancer markets.

The most recent analyst rating on (HK:9966) stock is a Buy with a HK$9.60 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.

More about Alphamab Oncology

Alphamab Oncology is a China-based biopharmaceutical company specializing in innovative antibody therapies for cancer, including bispecific antibodies developed on its proprietary CRIB platform. Its pipeline targets HER2-positive and HER2-low tumors, with a focus on breast and gastric cancers where it partners with CSPC Group’s JMT-Bio for development and commercialization in Mainland China.

Average Trading Volume: 1,371,116

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.5B

For an in-depth examination of 9966 stock, go to TipRanks’ Overview page.